

1                                   **BEFORE THE BOARD OF MEDICAL EXAMINERS**  
2                                   **OF THE STATE OF NEVADA**

3                                   \* \* \* \* \*

4 **In the Matter of Charges and**  
5 **Complaint Against**  
6 **Richard Allan Bargaen, M.D.,**  
7 **Respondent.**

Case No. 20-5783-1

**FILED**  
**JUN 10 2020**  
**NEVADA STATE BOARD OF**  
**MEDICAL EXAMINERS**  
By: \_\_\_\_\_

8  
9                                   **COMPLAINT**

10           The Investigative Committee<sup>1</sup> (IC) of the Nevada State Board of Medical Examiners (Board)  
11 hereby issues this formal Complaint (Complaint) against Richard Allan Bargaen, M.D. (Respondent),  
12 a physician licensed in Nevada. After investigating this matter, the IC has a reasonable basis to  
13 believe that Respondent has violated provisions of Nevada Revised Statutes (NRS) Chapter 630 and  
14 Nevada Administrative Code (NAC) Chapter 630 (collectively, the Medical Practice Act). The IC  
15 alleges the following facts:

16           1.       Respondent is a physician licensed to practice medicine in the State of Nevada  
17 (License No. 3877). He has been continuously licensed by the Board since September 15, 1979.

18           2.       Patient A's true identity is not disclosed herein to protect her privacy, but is  
19 disclosed in the Patient Designation served upon Respondent along with a copy of this  
20 Complaint.

21           3.       On October 31, 2016, Patient A was seen at the Spine Nevada Institute (SNI) with  
22 a diagnosis of chronic neck and back pain with a possible reticular etiology. No opioid treatment  
23 for Patient A was indicated within Patient A's medical records.

24           4.       On January 25, 2017, Patient A established care at the High Desert Clinic (Clinic).  
25 Medical records indicated Patient A slipped on ice and had an ankle sprain; however, these  
26 medical records do not indicate or explain Patient A's treatment plan. The Nevada Prescription

27 \_\_\_\_\_  
28 <sup>1</sup> The Investigative Committee (IC) of the Nevada State Board of Medical Examiners (Board), at the time this formal  
Complaint was authorized for filing, was composed of Dr. Rachakonda Prabhu, M.D., Chairman, Dr. Victor Muro,  
M.D., and Ms. April Mastrolucca.

1 Monitoring Program (PMP) report shows that Respondent prescribed and filled a 27 MME  
2 (morphine milligram equivalents) dosage of codeine (an opioid-based cough medicine). Further,  
3 Respondent's medical records do not document any consideration or an assessment of non-opioid  
4 therapy, a discussion or an assessment of risks and benefits, or a review of the PMP data for  
5 Patient A. Lastly, there is no medical justification indicated for Patient A's opioid treatment as  
6 prescribed by Respondent.

7 5. On February 9, 2017, Patient A visited the Clinic for foot & ankle pain, headaches  
8 and back pain. The PMP report for this date indicated Patient A obtained a prescription and filled  
9 15 MME of hydrocodone-acetaminophen from Respondent. Respondent prescribed Lyrica  
10 (150mg). The medical record states "PMP clean," but such an entry demonstrates that Respondent  
11 failed to see that an opioid drug was prescribed along with a benzodiazepine drug (temazepam).

12 6. On February 23, 2017, Patient A was seen by an unidentifiable care provider at the  
13 Clinic and the medical record was unsigned for this patient encounter. The PMP report indicates  
14 Patient A was prescribed 60 MME of oxycodone by Respondent and was prescribed 15 MME of  
15 codeine by Mr. B. Such an amount of MME is a substantial increase of dosage from the previous  
16 encounter (2/9/2017). The medical record does not document any consideration or an assessment  
17 of non-opioid therapy, a discussion or an assessment of risks and benefits, or a review of the PMP  
18 data. There is no evidence of medical decision-making to justify the dose escalation to using  
19 potentially excessively high doses of opioid therapy.

20 7. On March 7, 2017, Patient A was prescribed temazepam (30 mg) by Respondent  
21 pursuant to the PMP for this date and there are no medical records for this prescription.

22 8. On March 23, 2017, the PMP report indicates Patient A was prescribed 60 MME of  
23 oxycodone by Respondent. The medical records do not have any consideration or an assessment  
24 of non-opioid therapy, a discussion or an assessment of risks and benefits, or a review of the PMP  
25 data. There is no evidence of medical decision-making to justify the dose escalation to using  
26 potentially excessively high dosages of opioid therapy.

27 9. On May 18, 2017, Patient A was seen by an unknown provider at the Clinic and  
28 was treated with an injection into the right lower back. The PMP for this date indicates Patient A

1 obtained and filled a prescription of 90 MME of oxycodone, an 18 MME prescription of codeine,  
2 and a prescription for temazepam from Respondent. The medical records do not have any  
3 consideration or an assessment of non-opioid therapy, a discussion or an assessment of risks and  
4 benefits, or a review of the PMP data. There is no evidence of medical decision-making to justify  
5 the dose escalation to using potentially excessively high dosages of opioid therapy.

6 10. On June 14, 2017, Patient A was seen by an unknown provider at the Clinic. The  
7 PMP indicates Respondent prescribed codeine (18 MME). There are no medical records for this  
8 encounter and prescription.

9 11. On June 20, 2017, Patient A was seen by an unknown provider at the Clinic. The  
10 medical record indicates that she was recently in the ER (Emergency Room) for possible  
11 pancreatitis. There is no provider name or signature on the medical record. The PMP for this date  
12 indicated Patient A obtained and filled a prescription of 90 MME of oxycodone as written by  
13 Respondent. The medical records do not have any consideration or an assessment of non-opioid  
14 therapy, a discussion or an assessment of risks and benefits, or a review of the PMP data. There is  
15 no evidence of medical decision-making to justify the dose escalation to using potentially  
16 excessively high dosages of opioid therapy.

17 12. On July 14, 2017, the PMP indicates that Patient A filled a “butalbital comp  
18 codeine” prescription as written by Respondent. The medical records do not have any  
19 consideration or an assessment of the use of non-opioid therapy, a discussion or an assessment of  
20 risks and benefits, or a review of the PMP data.

21 13. On July 19, 2017, and on July 24, 2017, the PMP indicates that Patient A received  
22 a 250 MME prescription of oxycodone written by Mr. B. Additionally, Patient A received  
23 prescriptions for zolpidem 10 tablets, #30; and another refill of 18 MME of “butalbital comp  
24 codeine” prescribed by Respondent. This 250 MME daily dosage of an opioid is another  
25 substantial increase in the opioid therapy treatment plan. The medical records do not have any  
26 consideration or an assessment of the use of non-opioid therapy, a discussion or an assessment of  
27 risks and benefits, or a review of the PMP data. There is no evidence of medical decision-making  
28 to justify the dose escalation to using potentially excessively high dosages of opioid therapy.

1           14.     On August 14, 2017, the PMP indicates Patient A filled another codeine (18 MME)  
2 prescription as written by Respondent. The medical records do not have any consideration of or  
3 an assessment of the use of non-opioid therapy, a discussion or an assessment of risks and  
4 benefits, or a review of the PMP data.

5           15.     On August 16, 2017, Patient A was seen by an unknown provider at the Clinic.  
6 The medical records do not indicate the provider's name and the signature is illegible. The PMP  
7 report indicates Patient A received a 280 MME prescription for oxycodone written by Mr. B, plus  
8 a prescription for zolpidem 10 tablets, #30. This 280 MME daily dosage of an opioid is another  
9 substantial increase in the opioid therapy treatment plan. The medical records do not have any  
10 consideration of or an assessment of the use of non-opioid therapy, a discussion or an assessment  
11 of risks and benefits, or a review of the PMP data. There is no evidence of medical decision-  
12 making to justify the dose escalation to using potentially excessively high dosages of opioid  
13 therapy.

14           16.     On September 12, 2017, the PMP indicates Patient A filled another codeine (18  
15 MME) prescription as written by Respondent. The medical records do not have any consideration  
16 of or an assessment of the use of non-opioid therapy, a discussion or an assessment of risks and  
17 benefits, or a review of the PMP data.

18           17.     On September 13, 2017, Patient A was seen by an unknown provider at the Clinic.  
19 The medical records do not indicate the provider's name and the signature is illegible. The PMP  
20 report indicates Patient A received a 280 MME prescription of oxycodone written by Mr. B, plus a  
21 prescription for zolpidem 10 tablets, #30. This 280 MME daily dosage of an opioid is another  
22 substantial increase in the opioid therapy treatment plan. The medical records do not have any  
23 consideration or an assessment of the use of non-opioid therapy, a discussion or an assessment of  
24 risks and benefits, or a review of the PMP data. There is no evidence of medical decision-making  
25 to justify the dose escalation to using potentially excessively high dosages of opioid therapy.

26           18.     On September 28, 2017, the PMP report indicates that Patient A filled a 360 MME  
27 prescription for oxycodone written by Mr. B. This 360 MME daily dosage of an opioid is another  
28 substantial increase in the opioid therapy treatment plan. The medical records do not have any

1 consideration or an assessment of the use of non-opioid therapy, a discussion or an assessment of  
2 risks and benefits, or a review of the PMP data. There is no evidence of medical decision-making  
3 to justify the dose escalation to using potentially excessively high dosages of opioid therapy.

4 19. On October 11, 2017, Patient A was seen by an unknown provider at the Clinic.  
5 The medical records do not indicate the provider's name and the signature is illegible. The PMP  
6 report indicates Patient A received a 270 MME prescription of oxycodone written by Mr. B, plus a  
7 prescription for zolpidem 10 tablets, #30, plus 18 MME of codeine prescribed by Respondent,  
8 written on August 16, 2017. This 270 MME daily dosage of an opioid is a substantial decrease in  
9 the opioid therapy treatment plan. The medical records do not have any consideration or an  
10 assessment of use of non-opioid therapy, a discussion or an assessment of risks and benefits, or a  
11 review of the PMP data. There is no evidence of medical decision-making to justify the dose de-  
12 escalation to using potentially inadequate dosages of opioid therapy.

13 20. On October 24, 2017, the PMP report indicates that Patient A filled a 180 MME  
14 prescription of oxycodone, written by Mr. B on this same date. There is no medical record for this  
15 encounter and the prescription of oxycodone. This 180 MME daily dosage of an opioid is  
16 substantial decrease in the opioid therapy treatment plan. The medical records do not have any  
17 consideration or an assessment of the use of non-opioid therapy, a discussion of risks and benefits,  
18 or a review of the PMP data. There is no evidence of medical decision-making to justify the dose  
19 de-escalation to using potentially inadequate dosages of opioid therapy.

20 21. On November 8, 2017, Patient A was seen by an unknown provider at the Clinic.  
21 The medical records do not indicate the provider's name and there was no signature. The PMP  
22 report indicates Patient A received a 270 MME prescription of oxycodone from Respondent, plus  
23 a prescription for zolpidem 10 tablets, #30 from Mr. B's prescription, dated October 11, 2017,  
24 plus received another 18 MME of codeine as prescribed by Respondent, written on August 16,  
25 2017. This 270 MME daily dosage of an opioid is a substantial increase in the opioid therapy  
26 treatment plan. The medical records do not have any consideration or an assessment of non-opioid  
27 therapy, a discussion or an assessment of risks and benefits, or a review of the PMP data. There is  
28

1 no evidence of medical decision-making to justify the dose escalation to using potentially  
2 excessively high dosages of opioid therapy.

3 22. On November 21, 2017, the PMP report indicates that Patient A filled a 180 MME  
4 prescription of oxycodone, written by Mr. B on this same date. There is no medical record for this  
5 encounter and the prescription of oxycodone. There is no medical record for this encounter and  
6 prescription. This 180 MME daily dosage of an opioid is a substantial decrease in the opioid  
7 therapy treatment plan. The medical records do not have any consideration or an assessment of  
8 non-opioid therapy, a discussion or an assessment of risks and benefits, or a review of the PMP  
9 data. There is no evidence of medical decision-making to justify the dose de-escalation to using  
10 potentially inadequate dosages of opioid therapy.

11 23. On December 6, 2017, Patient A is seen by Respondent on her final visit to the  
12 Clinic. The PMP report indicates Patient A received a 270 MME prescription of oxycodone  
13 written by Mr. B, plus a prescription for zolpidem 10 tablets, #30 from Mr. B's prescription, dated  
14 October 11, 2017, plus 18 MME of codeine prescribed by Dr. B on August 16, 2017. This 270  
15 MME daily dosage of an opioid is a substantial increase in the opioid therapy treatment plan. The  
16 medical records do not have any consideration or an assessment of non-opioid therapy, a  
17 discussion of or an assessment of risks and benefits, or a review of the PMP data. There is no  
18 evidence of medical decision-making to justify the dose escalation to using potentially excessively  
19 high dosages of opioid therapy.

20 24. On December 11, 2017, Patient A died. The Churchill County Sheriff/Coroner  
21 certificate states that "based upon the considerations of the circumstances surrounding death,  
22 review of available medical history/records, autopsy examination, toxicological analysis, and  
23 other ancillary testing, the death of [Patient A] is ascribed to multiple drug toxicity (venlafaxine,  
24 amitriptyline, oxycodone and zolpidem). Based upon the circumstances of death as currently  
25 known, there is insufficient evidence to suggest suicidal intent; hence, the manner of death is best  
26 classified as accident." The Churchill County Sheriff's Office Report (Form 42) Supplement  
27 indicates that there was a bottle of controlled substances (venlafaxine) prescribed by Respondent  
28 found at the residence of Patient A and such inspection indicated the following:

Rx Date	Name of Med.	Rx#	Rx#	Dose	Physician
11/8/17	Venlafaxine	90	65	(1) 3x day	Dr. Bargaen

**COUNT I**

**NRS 630.301(4) (Malpractice)**

25. All of the allegations contained in the above paragraphs are hereby incorporated by reference as though fully set forth herein.

26. NRS 630.301(4) provides that malpractice of a physician is grounds for initiating disciplinary action against a licensee.

27. NAC 630.040 defines malpractice as the failure of a physician, in treating a patient, to use the reasonable care, skill, or knowledge ordinarily used under similar circumstances.

28. As demonstrated by, but not limited to, the above-outlined facts, Respondent failed to use the reasonable care, skill or knowledge ordinarily used under similar circumstances when he provided medical services to Patient A, who had a several encounters at the Clinic.

The Respondent's specific acts of malpractice are as follows, but not limited to:

1) prescribing excessively high doses of opioid therapy over 90 MME in violation of the *Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain*, July 2013; 2) failing to justify the use and increase, decrease, and then increase of dosages of opioid medication; 3) prescribing a combination of benzodiazepines and opioids without documenting the medical justification; 4) failing to review the PMP prior to, during, and after the encounters with Patient A; 5) failing to assess Patient A for an alternative for non-opioid treatments; 6) failing to assess and discuss with Patient A with the risks versus benefits of opioid therapy; 7) failing to assess Patient A's concurrent medications interactions with the opioid therapy; 8) failing to assess Patient A for possible drug abuse, drug diversion or any other non-medical related activity; 9) failing to review the PMP data; and, 10) failing to assess Patient A for possible drug screens on a consistent basis.

29. By reason of the foregoing, Respondent is subject to discipline by the Board as provided in NRS 630.352.






1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

WHEREFORE, the Investigative Committee prays:

1. That the Board give Respondent notice of the charges herein against him and give him notice that he may file an answer to the Complaint herein as set forth in NRS 630.339(2) within twenty (20) days of service of the Complaint;
2. That the Board set a time and place for a formal hearing after holding an Early Case Conference pursuant to NRS 630.339(3);
3. That the Board determine what sanctions to impose if it determines there has been a violation or violations of the Medical Practice Act committed by Respondent;
4. That the Board make, issue and serve on Respondent its findings of fact, conclusions of law and order, in writing, that includes the sanctions imposed; and
5. That the Board take such other and further action as may be just and proper in these premises.

DATED this 4 day of June, 2020.

INVESTIGATIVE COMMITTEE OF THE  
NEVADA STATE BOARD OF MEDICAL EXAMINERS

By:   
Robert Kilroy, Esq., General Counsel  
Attorney for the Investigative Committee

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**VERIFICATION**

STATE OF NEVADA            )  
  : ss.  
COUNTY OF CLARK        )

Richakonda D. Prabhu, M.D., having been duly sworn, hereby deposes and states under penalty of perjury that he is the Chairman of the Investigative Committee of the Nevada State Board of Medical Examiners that authorized the Complaint against the Respondent herein; that he has read the foregoing Complaint; and that based upon information discovered in the course of the investigation into a complaint against Respondent, he believes that the allegations and charges in the foregoing Complaint against Respondent are true, accurate and correct.

DATED this 4<sup>th</sup> day of June, 2020.

INVESTIGATIVE COMMITTEE OF THE  
NEVADA STATE BOARD OF MEDICAL EXAMINERS



Richakonda D. Prabhu, M.D., Chairman